Skip To Main Content
Určeno pro odbornou veřejnost
Campus
Campus
View Full Results

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Efluelda® TIV scientific flyer

Efluelda® TIV scientific flyer

Číst více
Efluelda® TIV scientific flyer

Efluelda® TIV scientific flyer

Číst více
Evidence-Based Antiplatelet Selection in ACS patients

Evidence-Based Antiplatelet Selection in ACS patients

Keep scrolling to explore ACS updates

Číst více
Impacto de la prevención de la infección por el virus sincicial respiratorio (VSR)​

Impacto de la prevención de la infección por el virus sincicial respiratorio (VSR)​

Evaluación del impacto en la salud pública de los programas de prevención de la infección por virus respiratorio sincicial (VRS) en lactantes de España y el Reino Unido

Číst více
Morbus Gaucher/ASMD: Unklare Splenomegalie: Gaucher oder ASMD?

Morbus Gaucher/ASMD: Unklare Splenomegalie: Gaucher oder ASMD?

Číst více
Rheumatologische Grunderkrankung oder lysosomale Speicherkrankheit?

Rheumatologische Grunderkrankung oder lysosomale Speicherkrankheit?

Číst více
Morbus Gaucher/ASMD: Wann werden blaue Flecken zu Red Flags?

Morbus Gaucher/ASMD: Wann werden blaue Flecken zu Red Flags?

Číst více
RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

Číst více
RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

Číst více
RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

Číst více
Guidelines for RSV prevention with Nirsevimab

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

Číst více
Guidelines for RSV prevention with Nirsevimab

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

Číst více